Aspen Pharmacare HoldingsJSE:APN +0.66%73 Net Margin % is 8.62% as of Dec. 2025, which is 33% below its 10-year median of 12.79. GuruFocus rates JSE:APN with a GF Score™ of 73/100 and a GF Value™ of R178.17 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 956 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 72.28% on this metric.
The historical rank and industry rank for Aspen Pharmacare Holdings's Net Margin % or its related term are showing as below:
JSE:APN'
s Net Margin % Range Over the Past 10 Years
Min: -4.69 Med: 12.79 Max: 18.2
Current: -4.69
JSE:APN's Net Margin % is ranked worse than 72.28% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs JSE:APN: -4.69
Aspen Pharmacare Holdings (JSE:APN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aspen Pharmacare Holdings Net Margin % Related Terms
Aspen Pharmacare Holdings Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:APN vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (JSE:APN) has a Net Margin % of 8.62% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Aspen Pharmacare Holdings and its competitors. This is 33% below median its historical median of 12.79. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #691 out of 956 companies in the Drug Manufacturers industry, placing it in the top 72.3%.
Is Aspen Pharmacare Holdings' Net Margin % too high?
Aspen Pharmacare Holdings' current Net Margin % of 8.62% is 33% below median its 10-year median of 12.79. The Drug Manufacturers industry median Net Margin % is 5.56. Aspen Pharmacare Holdings' value of 8.62% is 55% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #691 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #691 out of 956 companies for Net Margin %. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median Net Margin % is 5.56. Aspen Pharmacare Holdings' value of 8.62% is 55% above this benchmark. While the company's 10-year median is 12.79 vs. the industry median of 5.56, Aspen Pharmacare Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current Net Margin % of 8.62% is 55% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current Net Margin % is 8.62%, which is 33% below median its own 10-year median of 12.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R178.17, compared to a current price of R154.85 — trading 13.1% below its estimated fair value. The current Net Margin % is 8.62%, which is 33% below median its 10-year median of 12.79 and 55% above the Drug Manufacturers industry median of 5.56. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current Net Margin % is 8.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R154.85 is trading 13.1% below its estimated GF Value™ of R178.17.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
Net Margin %: 8.62% (33% below median its 10-year median of 12.79)
GF Value™: R178.17 vs. price of R154.85 (13.1% below fair value)
Industry Position: 55% above the Drug Manufacturers median (#691 of 956)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score
Get the complete analysis for JSE:APN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
